|
Gene: EHMT1 |
Gene summary for EHMT1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | EHMT1 | Gene ID | 79813 |
Gene name | euchromatic histone lysine methyltransferase 1 | |
Gene Alias | EHMT1-IT1 | |
Cytomap | 9q34.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9H9B1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79813 | EHMT1 | CCI_1 | Human | Cervix | CC | 5.45e-05 | 5.82e-01 | 0.528 |
79813 | EHMT1 | CCI_2 | Human | Cervix | CC | 5.70e-08 | 6.77e-01 | 0.5249 |
79813 | EHMT1 | CCI_3 | Human | Cervix | CC | 1.52e-19 | 1.05e+00 | 0.516 |
79813 | EHMT1 | CCII_1 | Human | Cervix | CC | 1.55e-02 | 3.27e-01 | 0.3249 |
79813 | EHMT1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.11e-22 | -6.93e-01 | 0.0155 |
79813 | EHMT1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.81e-08 | -4.92e-01 | -0.1808 |
79813 | EHMT1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.31e-03 | -4.28e-01 | -0.1088 |
79813 | EHMT1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.67e-07 | -6.01e-01 | -0.1207 |
79813 | EHMT1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.34e-03 | -6.48e-01 | -0.2061 |
79813 | EHMT1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.15e-03 | -7.10e-01 | -0.1462 |
79813 | EHMT1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.74e-05 | -5.86e-01 | -0.0179 |
79813 | EHMT1 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.37e-07 | -4.63e-01 | 0.096 |
79813 | EHMT1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 6.23e-04 | -6.63e-01 | 0.0528 |
79813 | EHMT1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.23e-12 | -4.53e-01 | 0.294 |
79813 | EHMT1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.42e-13 | -4.92e-01 | 0.3005 |
79813 | EHMT1 | A001-C-207 | Human | Colorectum | FAP | 7.81e-05 | -1.82e-01 | 0.1278 |
79813 | EHMT1 | A015-C-203 | Human | Colorectum | FAP | 5.01e-33 | -2.10e-01 | -0.1294 |
79813 | EHMT1 | A015-C-204 | Human | Colorectum | FAP | 1.24e-04 | -1.87e-01 | -0.0228 |
79813 | EHMT1 | A014-C-040 | Human | Colorectum | FAP | 1.56e-03 | -9.55e-02 | -0.1184 |
79813 | EHMT1 | A002-C-201 | Human | Colorectum | FAP | 3.46e-13 | -1.03e-01 | 0.0324 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00016594 | Oral cavity | OSCC | temperature homeostasis | 84/7305 | 174/18723 | 7.84e-03 | 2.87e-02 | 84 |
GO:00349687 | Oral cavity | OSCC | histone lysine methylation | 58/7305 | 115/18723 | 8.25e-03 | 3.01e-02 | 58 |
GO:19908454 | Oral cavity | OSCC | adaptive thermogenesis | 76/7305 | 157/18723 | 1.02e-02 | 3.52e-02 | 76 |
GO:001657023 | Oral cavity | EOLP | histone modification | 98/2218 | 463/18723 | 5.58e-09 | 2.96e-07 | 98 |
GO:000632515 | Oral cavity | EOLP | chromatin organization | 84/2218 | 409/18723 | 2.68e-07 | 8.16e-06 | 84 |
GO:001820521 | Oral cavity | EOLP | peptidyl-lysine modification | 72/2218 | 376/18723 | 2.38e-05 | 3.56e-04 | 72 |
GO:004667712 | Oral cavity | EOLP | response to antibiotic | 14/2218 | 47/18723 | 7.86e-04 | 6.25e-03 | 14 |
GO:003496813 | Oral cavity | EOLP | histone lysine methylation | 26/2218 | 115/18723 | 8.11e-04 | 6.35e-03 | 26 |
GO:001657113 | Oral cavity | EOLP | histone methylation | 30/2218 | 141/18723 | 9.78e-04 | 7.39e-03 | 30 |
GO:000963625 | Oral cavity | EOLP | response to toxic substance | 48/2218 | 262/18723 | 1.37e-03 | 9.49e-03 | 48 |
GO:000647913 | Oral cavity | EOLP | protein methylation | 35/2218 | 181/18723 | 2.30e-03 | 1.42e-02 | 35 |
GO:000821313 | Oral cavity | EOLP | protein alkylation | 35/2218 | 181/18723 | 2.30e-03 | 1.42e-02 | 35 |
GO:00180226 | Oral cavity | EOLP | peptidyl-lysine methylation | 26/2218 | 131/18723 | 5.52e-03 | 2.86e-02 | 26 |
GO:00459957 | Oral cavity | EOLP | regulation of embryonic development | 15/2218 | 64/18723 | 6.83e-03 | 3.32e-02 | 15 |
GO:001657031 | Oral cavity | NEOLP | histone modification | 88/2005 | 463/18723 | 5.59e-08 | 2.23e-06 | 88 |
GO:000963633 | Oral cavity | NEOLP | response to toxic substance | 56/2005 | 262/18723 | 3.13e-07 | 9.85e-06 | 56 |
GO:000632521 | Oral cavity | NEOLP | chromatin organization | 70/2005 | 409/18723 | 4.97e-05 | 6.83e-04 | 70 |
GO:000647922 | Oral cavity | NEOLP | protein methylation | 37/2005 | 181/18723 | 8.15e-05 | 1.02e-03 | 37 |
GO:000821322 | Oral cavity | NEOLP | protein alkylation | 37/2005 | 181/18723 | 8.15e-05 | 1.02e-03 | 37 |
GO:004599513 | Oral cavity | NEOLP | regulation of embryonic development | 18/2005 | 64/18723 | 9.10e-05 | 1.12e-03 | 18 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00310 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
hsa04211 | Colorectum | AD | Longevity regulating pathway | 33/2092 | 89/8465 | 6.15e-03 | 2.68e-02 | 1.71e-02 | 33 |
hsa003101 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
hsa042111 | Colorectum | AD | Longevity regulating pathway | 33/2092 | 89/8465 | 6.15e-03 | 2.68e-02 | 1.71e-02 | 33 |
hsa042112 | Colorectum | MSS | Longevity regulating pathway | 33/1875 | 89/8465 | 9.33e-04 | 5.58e-03 | 3.42e-03 | 33 |
hsa003102 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
hsa042113 | Colorectum | MSS | Longevity regulating pathway | 33/1875 | 89/8465 | 9.33e-04 | 5.58e-03 | 3.42e-03 | 33 |
hsa003103 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
hsa003104 | Colorectum | FAP | Lysine degradation | 23/1404 | 63/8465 | 1.04e-04 | 9.46e-04 | 5.76e-04 | 23 |
hsa042114 | Colorectum | FAP | Longevity regulating pathway | 27/1404 | 89/8465 | 8.82e-04 | 5.20e-03 | 3.16e-03 | 27 |
hsa003105 | Colorectum | FAP | Lysine degradation | 23/1404 | 63/8465 | 1.04e-04 | 9.46e-04 | 5.76e-04 | 23 |
hsa042115 | Colorectum | FAP | Longevity regulating pathway | 27/1404 | 89/8465 | 8.82e-04 | 5.20e-03 | 3.16e-03 | 27 |
hsa003106 | Colorectum | CRC | Lysine degradation | 18/1091 | 63/8465 | 7.21e-04 | 6.34e-03 | 4.30e-03 | 18 |
hsa042116 | Colorectum | CRC | Longevity regulating pathway | 20/1091 | 89/8465 | 8.36e-03 | 3.93e-02 | 2.66e-02 | 20 |
hsa003107 | Colorectum | CRC | Lysine degradation | 18/1091 | 63/8465 | 7.21e-04 | 6.34e-03 | 4.30e-03 | 18 |
hsa042117 | Colorectum | CRC | Longevity regulating pathway | 20/1091 | 89/8465 | 8.36e-03 | 3.93e-02 | 2.66e-02 | 20 |
hsa0421114 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa0031010 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
hsa0421115 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa0031013 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EHMT1 | SNV | Missense_Mutation | c.2330N>G | p.Leu777Arg | p.L777R | Q9H9B1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
EHMT1 | SNV | Missense_Mutation | novel | c.3146N>T | p.Pro1049Leu | p.P1049L | Q9H9B1 | protein_coding | deleterious(0.03) | possibly_damaging(0.868) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EHMT1 | SNV | Missense_Mutation | novel | c.848C>T | p.Ala283Val | p.A283V | Q9H9B1 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.99) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
EHMT1 | SNV | Missense_Mutation | c.3092G>T | p.Ser1031Ile | p.S1031I | Q9H9B1 | protein_coding | deleterious(0.01) | possibly_damaging(0.799) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EHMT1 | SNV | Missense_Mutation | novel | c.877N>G | p.Met293Val | p.M293V | Q9H9B1 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.867) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EHMT1 | SNV | Missense_Mutation | novel | c.769C>A | p.His257Asn | p.H257N | Q9H9B1 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.476) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
EHMT1 | SNV | Missense_Mutation | novel | c.3704G>C | p.Gly1235Ala | p.G1235A | Q9H9B1 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
EHMT1 | SNV | Missense_Mutation | rs761131393 | c.838N>T | p.Val280Phe | p.V280F | Q9H9B1 | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.564) | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
EHMT1 | SNV | Missense_Mutation | c.1037N>C | p.Met346Thr | p.M346T | Q9H9B1 | protein_coding | tolerated_low_confidence(0.11) | benign(0.022) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EHMT1 | SNV | Missense_Mutation | rs761131393 | c.838G>T | p.Val280Phe | p.V280F | Q9H9B1 | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.564) | TCGA-C8-A137-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
79813 | EHMT1 | ENZYME, DRUGGABLE GENOME | inhibitor | 249565918 | ||
79813 | EHMT1 | ENZYME, DRUGGABLE GENOME | inhibitor | 178103593 | CHEMBL569864 | |
79813 | EHMT1 | ENZYME, DRUGGABLE GENOME | inhibitor | 178103596 | ||
79813 | EHMT1 | ENZYME, DRUGGABLE GENOME | inhibitor | 178103594 |
Page: 1 |